Dear investors and analysts,

We hope you’ve had a great first half of the year – it’s been busy. We hosted another investor education event, spotlighted global health at our Infectious Diseases day, and continued great dialogue about our work related to ESG with many of you. As with last quarter, we hope this addendum will serve as a tool to highlight ESG activity including updates that were published this quarter.

We’d love to hear from you so please reach out to our team with your comments and questions.

Thank you,

GSK Investor Relations
IRTeam@gsk.com

Six areas of focus

We are guided by our purpose to unite science, technology, and talent to get ahead of disease together. Integral to this is running a responsible business, one which builds trust and reduces risk to deliver sustainable health impact at scale, shareholder returns, and to support our people to thrive. To do so, we have prioritised our resources to focus on six material areas:

- Access
- Global health and health security
- Diversity, equity and inclusion
- Environment
- Product governance
- Ethical standards
ESG highlights from our Q2 2023 results presentation

Access
- In July, Gavi announced the first nine new countries to be allocated doses of the RTS,S/AS01E vaccine against malaria from early 2024

Global Health and Health Security
- Gates Foundation and Wellcome announced funding for the ph III trial of M72/AS01E candidate vaccine against tuberculosis, which GSK developed up to proof-of-concept

Environment
- Selected by the Science Based Target Network to set science-based targets for nature, building on our existing nature targets.
Spotlight: Global health

On 27 June, we hosted a virtual Infectious Diseases (ID) day for investors that included an overview of our ID portfolio and four breakout sessions featuring more details on selected areas. One of the breakout sessions focused on our work “delivering health impact at scale” including spotlights on our dedication to our work on HIV, malaria and tuberculosis. The full presentation can be found here and a recording of the presentation is available here.

HIV
• The greatest barrier to treating and preventing HIV is access to and uptake of affordable medicines
• >80% of treatment is with a dolutegravir based regimen
• Providing access to innovative long-acting injectable for prevention
• 50% of children on HIV treatment take a generic version of dispersible dolutegravir

Malaria
• A child dies of malaria every minute in sub-Saharan Africa, the region that bears the overwhelming burden of the disease
• First and only P.falciparum malaria vaccine for children
• Radical cure for P.vivax malaria

Tuberculosis
• TB should be preventable and curable yet it is the second leading infectious killer after COVID-19
• Vaccines innovation: First candidate TB vaccine in 100 years
• Changing the treatment paradigm in TB
Recent questions from investors

1. How does reach data get collected for Medicines Patent Pool (MPP) agreements – who is responsible for this? how is it happening?

The MPP is responsible for tracking the development and uptake of licensed products via quarterly meetings with its sub-licensees. ViiV Healthcare meets quarterly with the MPP to share and discuss this data as well as to govern and manage other aspects of our licences.

The MPP collects and shares data on Stringent Regulatory Authority (SRA) and national registrations for all licensed products with ViiV as well as sharing aggregated sales volumes for the quarter across all licensees for each product. From the licensee sales data, estimates can be made around both the number of doses delivered, and the corresponding number of people treated (reported as patient-years, where one patient-year corresponds to the quantity of medicines needed to treat one person for one year). The breadth of impact geographically can also be mapped via the data collected.

Twice a year, the MPP publishes a summary on its website which highlights the progress of all MPP’s generic partners in developing, manufacturing and supplying MPP-licensed medicines. This includes data for the products which ViiV has licensed to the MPP.

2. What is the current status of the roll out of the malaria vaccines (RTS,S)?

We are very proud to have developed, in collaboration with our partners, RTS,S/AS01E (RTS,S), the first vaccine against malaria.

Getting ahead of malaria is a long-standing priority for GSK - to date, GSK has worked on RTS,S for over 35 years, invested more than $700m and is donating up to 10m doses to the ongoing WHO-coordinated Malaria Vaccine Implementation Programme, which will complete at the end of this year. To date, more than 1.7 million children have received at least one dose of RTS,S through routine immunisation in the MVIP countries – Ghana, Kenya and Malawi.

From early 2024, nine more malaria endemic countries in sub-Saharan Africa will start to roll out the vaccine as part of their routine immunisation programmes, supported by Gavi.

3. What is happening with the candidate TB vaccine, M72?

Since announcing our partnership with Gates MRI for M72/AS01E4’s further development in 2020, we have been working together to transfer the technology and expertise to manufacture the M72 antigen to Gates MRI.

We’ve made good progress to date with Gates MRI now manufacturing M72 and continue to work together to progress the vaccine to Phase 3 trials.
Committed to ESG investor engagement

On 6 June 2023, we hosted an investor education event on clinical trial diversity. During the session Alberto Fernandez, SVP of Global Clinical Operations at GSK and Dr. Kimberly Smith, SVP and Head of R&D at ViiV Healthcare, provided insights on the importance of clinical trial diversity including support from a 17-year retrospective study.

Alberto and Kim also provided an overview of GSK’s work to ensure clinical trials reflect the populations most impacted by a disease and explored an HIV case study that demonstrates the power of clinical trial diversity in action.

Watch the webinar replay

Access the presentation

Please note: our AMR Investor Education event originally planned for July has been postponed. We will send a save the date email when a reschedule date is confirmed. And, if you are not on our ESG email distribution list, please let us know and we’ll add you.